<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>685</ReferenceId>
        <DateLastUpdated>2016-11-03-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15225558</PubmedId>
            <Abstract>Botulinum neurotoxins (BoNTs), the causative agents for life-threatening human disease botulism, have been recognized as biological warfare agents. In this study, a neutralizing mouse monoclonal antibody against botulinum neurotoxin serotype B (BoNT/B), named BTBH-N1, was developed from mice immunized with BoNT/B toxoid without non-toxic components, which are generally associated with the toxin. Western blot analysis, using recombinant toxin fragments containing light (L), N-terminal half of heavy (HN) and C-terminal half of heavy chains, indicated that BTBH-N1 recognizes linear epitopes located on the HN domain. An in vivo neutralization assay with mice, was conducted to characterize the neutralization capacity of the BTBH-N1. Only 10 microg of BTBH-N1 completely neutralized 20 units (1 unit = one 50% lethal dose) of BoNT/B. Even though the Mab (up to 100 microg) failed to protect mice challenged with 100 units, it significantly prolonged the time to death in a dose dependent manner. BTBH-N1, the first neutralizing antibody against BoNT/B, could be further developed as effective biological therapeutics for preventing and treating botulism, as well as other diseases caused by BoNT/B.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>19-25</ArticlePages>
            <ArticleTitle>Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Gi-Hyeok</ForeName>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Kyu-Sik</ForeName>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Hak-Woo</ForeName>
                </Author>
                <Author>
                    <LastName>Jeong</LastName>
                    <ForeName>Sung Tae</ForeName>
                </Author>
                <Author>
                    <LastName>Huh</LastName>
                    <ForeName>Gyung Heng</ForeName>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Ji Cheon</ForeName>
                </Author>
                <Author>
                    <LastName>Jung</LastName>
                    <ForeName>Hyun Ho</ForeName>
                </Author>
            </Authors>
            <Affiliations>Microbial Toxin Research Institute, Chungnam 336-708, South Korea.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Epitopes;rimabotulinumtoxinB;Botulinum Toxins;Botulinum Toxins, Type A</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Monoclonal(isolation &amp; purification; metabolism); Blotting, Western; Botulinum Toxins(metabolism); Botulinum Toxins, Type A; Botulism(immunology; prevention &amp; control); Clostridium botulinum(chemistry); Cross Reactions(immunology); Disease Models, Animal; Electrophoresis, Polyacrylamide Gel; Epitopes(metabolism); Immunization; Mice; Neutralization Tests; Time Factors</ArticleMeshHeadingsList>
            <Journal>
                <Volume>44</Volume>
                <Issue>1</Issue>
                <Title>Toxicon : official journal of the International Society on Toxinology</Title>
                <Issn>0041-0101</Issn>
                <MedlineTa>Toxicon</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>BoNT/B H&lt;sub&gt;N&lt;/sub&gt; (translocation) domain of Heavy chain</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>APGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELN</LinearSequence>
                        <StartingPosition>442</StartingPosition>
                        <EndingPosition>894</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P10844.3</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10000303</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <EpitopeId>3570</EpitopeId>
                <ReferenceStartingPosition>441</ReferenceStartingPosition>
                <ReferenceEndingPosition>893</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The recombinant fragment used in this study encompasses the H&lt;sub&gt;N&lt;/sub&gt; domain of BoNT/B (residues 441-883 in swiss-prot entry P10844 excluding the initiation methionine) with an extended C-terminal, ending 10 residues into the H&lt;sub&gt;C&lt;/sub&gt; domain up to residue 893.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1277800</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P10844.3</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>10000303</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>BoNT/B toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 10 μg toxoid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The immunogen is the BoNT/B toxoid, prepared by formaldehyde inactivation of BoNT/B purified toxin (without non-toxic components). The first dose was given in CFA, the second in IFA and the 3rd without adjuvant. The 3rd dose was given intravenously, 5 days prior to hybridoma generation by fusion with Sp2/0-Ag14 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Recombinant fragments of BoNT/B (Lc, HN and HC domains) expressed in E.coli were blotted with the monoclonal Ab BTBH-N1, which is shown to react exclusively with the HN domain.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BTBH-N1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>BoNT/B H&lt;sub&gt;N&lt;/sub&gt; (translocation) domain of Heavy chain</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>APGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELN</LinearSequence>
                                        <StartingPosition>442</StartingPosition>
                                        <EndingPosition>894</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P10844.3</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000303</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1277801</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P10844.3</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>10000303</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>BoNT/B toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 10 μg toxoid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The immunogen is the BoNT/B toxoid, prepared by formaldehyde inactivation of BoNT/B purified toxin (without non-toxic components). The first dose was given in CFA, the second in IFA and the 3rd without adjuvant. The 3rd dose was given intravenously, 5 days prior to hybridoma generation by fusion with Sp2/0-Ag14 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>253</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>5.0</QuantitativeMeasurement>
                            <AssayComments>Purified BoNT/B affinity towards the monoclonal Ab BTBH-N1, which was shown to react exclusively with the epitopic domain, was determined by competitive indirect ELISA. The toxin is also recognized in WB, while BoNT/A and E type toxins are not.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BTBH-N1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Botulinum neurotoxin type B</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P10844.3</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10000303</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1277802</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P10844.3</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>10000303</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>BoNT/B toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 10 μg toxoid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The immunogen is the BoNT/B toxoid, prepared by formaldehyde inactivation of BoNT/B purified toxin (without non-toxic components). The first dose was given in CFA, the second in IFA and the 3rd without adjuvant. The 3rd dose was given intravenously, 5 days prior to hybridoma generation by fusion with Sp2/0-Ag14 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Purified BoNT/B lethality is inhibited by the monoclonal Ab BTBH-N1, which was shown to react exclusively with the epitopic domain. For a 20LD50 injection, preincubation with 10 and 100μg mAb completely inhibited the toxin lethality, while preincubationof 20 LD50 with 1 μg or of  100 LD50 with up to 100μg of mAb fails to inhibit the deaths but delayed them significantly in a dose dependent manner.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BTBH-N1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Botulinum neurotoxin type B</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P10844.3</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10000303</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

